With $1.6 million award, biochemist tackles diabetes

January 09, 2014

PROVIDENCE, R.I. [Brown University] - People with type 2 diabetes can make insulin but their bodies use it so poorly that glucose levels run amok. It's been difficult for scientists to understand what's going awry in the way that tiny, fast-moving proteins signal and regulate glucose metabolism. As a result, while drugs can help somewhat, many patients still must monitor their glucose and inject insulin.

Brown University biochemist Wolfgang Peti is new to the fight, but he's well-armed and well-motivated to join it.

As it is for millions of people around the world, the pervasive condition is personal for Peti. His grandmother battled it for decades.

"It affected her ability to see, her ability to walk through the mountains of Austria, and her ability to eat all the traditional foods she grew up eating and cooking," Peti said. "And while she successfully battled the disease for many years, eventually the doctors had to amputate both of her legs (first at age 80, second at age 88) and she was confined to a wheelchair for the last eight years of her life."

Although he hasn't focused specifically on diabetes before, decades of research have given him a deep expertise in the atomic structure and behavior of some of the key proteins of insulin signaling. He and his collaborators have refined these proteins in the lab to the degree that they and their interactions can now be fully analyzed with advanced techniques such as nuclear magnetic resonance spectroscopy and X-ray crystallography.

Last year, when Brown acquired a powerful new NMR magnet, Peti gained a rare degree of capability to study the dynamic motions of these proteins and the timing of their interactions, as well as their basic structure. That's exactly what he now plans to do with a five-year, $1.625-million New to Diabetes Research Accelerator Award announced Jan. 9, 2014, by the American Diabetes Association. Peti is one of only five researchers around the country to win an ADA Accelerator Award this year.

Wolfgang Peti"The easiest thing would be ... instead of injecting insulin, you'd just take a tablet. If you can control the insulin-signaling pathway with a drug, that would make your life much easier."Wolfgang Peti "The easiest thing would be ... instead of injecting insulin, you'd just take a tablet. If you can control the insulin-signaling pathway with a drug, that would make your life much easier."Peti's ambitious goal is to enable the development of medicines that improve on the status quo so greatly that insulin injections might no longer necessary.

"The easiest thing would be if you have type 2 diabetes instead of injecting insulin, you'd just take a tablet," he said. "If you can control the insulin-signaling pathway with a drug, that would make your life much easier."

Three targets

Many brilliant scientists share this goal, but so far the field has fallen short. Still, for all the well-worn dead ends, Peti still sees the insulin-signaling pathway as rife with potential new leads. He plans to look in novel ways and in novel places at the interactions of three main proteins in particular.

One target is the binding between insulin and the insulin receptor. That step activates the "TK" domain, or section, of the receptor, kicking off the cascade of protein signaling that leads to the metabolism of glucose. This may seem like an obvious place to start, but the complexity comes from trying to observe the movements of the TK domain and the specific timing that may be going awry in type 2 diabetes.

Peti and his colleagues have been able to model it all in E. coli bacteria, which will allow them to observe it precisely with NMR. That will allow Peti see how the TK domain reshapes and moves, how quickly and when. That could yield a clear understanding of whether a drug could block or slow a key movement that is happening too soon or too quickly.

Peti also plans to work with fellow Brown biologist Marc Tatar to take the ideas into the fruit fly where they can investigate the differences made by known genetic mutations.

Another target is an enzyme called PTP1B, which can shut off insulin signaling. Because the goal in treating type 2 diabetes is to improve insulin function, Peti wants to stop PTP1B.

PTP1B has proven time and again to be tough to block without unintended consequences, but Peti hopes a less direct approach than others have taken will make a difference. Rather than targeting the main catalytic parts of the enzyme directly, he's looking at the behavior of a more peripheral but nevertheless influential structure called the "c-terminal segment." It's an underexplored region that could be targeted very specifically, likely with a combination of surgical strikes on more than one area. A key requirement of any drug is that it only affects insulin signaling and not other interactions by similar enzymes.

Sure enough, along with colleague Nicholas Tonks at the Cold Spring Harbor Laboratory, Peti has begun to characterize a drug that works in this area. They plan to use NMR to improve the understanding of the drug's workings further and use that knowledge to improve its abilities.

Peti's third approach under the ADA award is more traditional in that it depends "simply" on characterizing the structure of a complex of proteins, together known as GM:PP1. That complex controls the balance between storing glucose in the form of a larger "glycogen" molecule and breaking glycogen down into glucose. GM:PP1 accomplishes the latter by turning on an enzyme called glycogen phosphorylase.

Peti's idea is to figure out how a drug could inhibit GM:PP1's recognition of glycogen phosphorylase so that it doesn't break down glycogen into glucose so readily. Peti already knows where he wants to look on the proteins to try the idea and has developed a means of screening drugs that might interact with those areas.

Success with any of the three approaches is hardly guaranteed, but if there is a chance he can save anyone else from the kind of difficulty his grandmother endured, Peti is eager to try.
-end-


Brown University

Related Diabetes Articles from Brightsurf:

New diabetes medication reduced heart event risk in those with diabetes and kidney disease
Sotagliflozin - a type of medication known as an SGLT2 inhibitor primarily prescribed for Type 2 diabetes - reduces the risk of adverse cardiovascular events for patients with diabetes and kidney disease.

Diabetes drug boosts survival in patients with type 2 diabetes and COVID-19 pneumonia
Sitagliptin, a drug to lower blood sugar in type 2 diabetes, also improves survival in diabetic patients hospitalized with COVID-19, suggests a multicenter observational study in Italy.

Making sense of diabetes
Throughout her 38-year nursing career, Laurel Despins has progressed from a bedside nurse to a clinical nurse specialist and has worked in medical, surgical and cardiac intensive care units.

Helping teens with type 1 diabetes improve diabetes control with MyDiaText
Adolescence is a difficult period of development, made more complex for those with Type 1 diabetes mellitus (T1DM).

Diabetes-in-a-dish model uncovers new insights into the cause of type 2 diabetes
Researchers have developed a novel 'disease-in-a-dish' model to study the basic molecular factors that lead to the development of type 2 diabetes, uncovering the potential existence of major signaling defects both inside and outside of the classical insulin signaling cascade, and providing new perspectives on the mechanisms behind insulin resistance in type 2 diabetes and possibly opportunities for the development of novel therapeutics for the disease.

Tele-diabetes to manage new-onset diabetes during COVID-19 pandemic
Two new case studies highlight the use of tele-diabetes to manage new-onset type 1 diabetes in an adult and an infant during the COVID-19 pandemic.

Genetic profile may predict type 2 diabetes risk among women with gestational diabetes
Women who go on to develop type 2 diabetes after having gestational, or pregnancy-related, diabetes are more likely to have particular genetic profiles, suggests an analysis by researchers at the National Institutes of Health and other institutions.

Maternal gestational diabetes linked to diabetes in children
Children and youth of mothers who had gestational diabetes during pregnancy are at increased risk of diabetes themselves, according to new research published in CMAJ (Canadian Medical Association Journal).

Two diabetes medications don't slow progression of type 2 diabetes in youth
In youth with impaired glucose tolerance or recent-onset type 2 diabetes, neither initial treatment with long-acting insulin followed by the drug metformin, nor metformin alone preserved the body's ability to make insulin, according to results published online June 25 in Diabetes Care.

People with diabetes visit the dentist less frequently despite link between diabetes, oral health
Adults with diabetes are less likely to visit the dentist than people with prediabetes or without diabetes, finds a new study led by researchers at NYU Rory Meyers College of Nursing and East Carolina University's Brody School of Medicine.

Read More: Diabetes News and Diabetes Current Events
Brightsurf.com is a participant in the Amazon Services LLC Associates Program, an affiliate advertising program designed to provide a means for sites to earn advertising fees by advertising and linking to Amazon.com.